Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis

•We explored eight scenarios of QIV vs. TIV using a decision tree model to simulate the health and economic impact of the introduction of QIV to school children, elderly adults, and health care workers in Beijing.•The main health benefits of the introduction of QIV are the decrease in infections and...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2022-02, Vol.40 (7), p.994-1000
Main Authors: Zhu, Dawei, Lv, Min, Bai, Yunhua, Wu, Jiang, He, Ping
Format: Article
Language:English
Subjects:
Adult
Adults
Aged
Beijing
Caregivers
Child
Children
Cost analysis
Cost-Benefit Analysis
Cost-effectiveness
COVID-19
Decision making
Decision trees
GDP
Gross Domestic Product
Health care
Health care expenditures
Health surveillance
Hospitalization
Humans
Immunization
Infections
Influenza
Influenza Vaccines
Influenza, Human - prevention & control
Medical laboratories
Medical personnel
Middle Aged
Mortality
Older people
Per capita
Public health
Quadrivalent influenza vaccine
Risk groups
SARS-CoV-2
Seasons
Sensitivity analysis
Statistical analysis
Trivalent influenza vaccine
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•We explored eight scenarios of QIV vs. TIV using a decision tree model to simulate the health and economic impact of the introduction of QIV to school children, elderly adults, and health care workers in Beijing.•The main health benefits of the introduction of QIV are the decrease in infections and hospitalization among school children, as well as hospitalization and death among elderly adults.•The introduction of QIVs to school children, elderly adults, and health care workers is likely to be cost-effective, either separately or collectively. Since 2007, Beijing has offered a free trivalent influenza vaccine (TIV) for residents aged ≥ 60 years and school students. The quadrivalent influenza vaccine (QIV) was administered to school children in 2018 and will be administered to elderly adults in the future. In addition, health care workers (HCWs) who are involved in the prevention and control of COVID-19 were included in the program in 2020. This study aimed to analyze the cost-effectiveness of a comprehensive list of combined strategies of TIV and QIV for school children, elderly adults, and HCWs to identify the most cost-effective strategy. A decision tree was developed to compare 1-year outcomes of TIV vs. QIV in three risk groups: school children, elderly adults, and HCWs. The outcome was incremental cost per quality-adjusted life-year (QALY). Probabilistic sensitivity analyses and scenario analyses were developed to assess the robustness of the results. From the perspective of society, this study found that the introduction of QIVs can be cost-effective for any and all targeted groups with a willingness-to-pay threshold of 3-fold GDP per capita. Among all programs, program H (all school children, elderly adults, and HCWs received the QIV) showed a 79% probability of being cost-effective with an incremental cost-effectiveness ratio (ICER) of 13,580 (95% CI: 13,294, 13,867) US$/QALY and was the preferred option in the base case scenario. The introduction of QIVs to school children, elderly adults, or HCWs is likely to be cost-effective, either separately or collectively. The introduction of QIV to school children, elderly adults, and health care workers simultaneously showed the highest probability of being cost-effective and was the preferred option.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2022.01.006